News and Events
As part of implementation of the Global Action Plan on Antimicrobial Resistance, WHO drew up a list of priority antibiotic-resistant pathogens (priority pathogens list; PPL) to guide research into and the discovery and development of new antibiotics.
As a further step, WHO analysed the pipeline of antibacterial products (antibiotics and biologicals) that were in phase I-III of clinical development (as of May 2017) and which had not, at that date, received market authorization for human use anywhere in the world. The analysis matched the products in development against the WHO priority pathogens list (PPL), Mycobacterium tuberculosis and Clostridium difficile.
Candidate products are reported by type, pathogen category, phase of clinical development, and expected activity against priority pathogens. There is also an assessment of their innovativeness and whether a new chemical entity is involved. The route of administration, antibiotic class and developers are also reported. The review shows that the current clinical pipeline is still insufficient to mitigate the threat of antimicrobial resistance.
The full report can be found here.
A summary of the data can be downloaded from the Global Observatory on Health R&D.
Antibiotic Alternative Micreos wins Most Impactful Innovation
In the presence of former UN-Secretary-General Kofi Annan and Dutch minister Melanie Schultz of Infrastructure & the Environment, Micreos' alternative to antibiotics was chosen as the most impactful innovation of The Netherlands. Micreos, an Immuno Valley partner will represent The Netherlands at the semi-finals of Ideas from Europe in Talinn, Estonia on November 22 2017.
EU Joint action on antimicrobial resistance launched
A joint action on antimicrobial resistance and healthcare-associated infections (EU-JAMRAI), bringing together member states, international organizations, institutes and universities to tackle the AMR threat was launched on 13 September, at the French Ministry of Health in Paris.
Innatoss is closer to new Q-fever vaccine without side-effects
The research team at Innatoss Laboratories, an Immuno Valley partner, is one step closer to developing a new Q-fever vaccine. Blood samples taken in 2015 from residents of Herpen were successfully analyzed in the USA . These analyses identified 15 parts of the Q-fever bacterium that can be used in a vaccine. It is expected that these will show fewer side-effects.
Liana Steeghs new member Board of Stakeholders TRANSVAC2
TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded under FP7. Liana Steeghs, Managing Director of Immuno Valley has accepted a position on the Board of Stakeholders of TRANSVAC2.
More than EUR 56 million raised to fund initiative to fight antibiotic resistance
Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research.